Skip to main content
TNDM
NASDAQ Industrial Applications And Services

Tandem Diabetes Care Reports Strong Q1 2026 Results, Achieves Positive Free Cash Flow, Reaffirms Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$20.04
Mkt Cap
$1.265B
52W Low
$9.98
52W High
$29.65
52W Position info
101% above low
Off High info
32% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

TNDM has more than doubled off its 52-week low of $9.98.

Summary

Tandem Diabetes Care reported record Q1 2026 sales and pump shipments, achieved positive free cash flow, and significantly narrowed its net loss, reaffirming its full-year financial guidance.


Key Events · Earnings and Guidance · TNDM

  • Strong Q1 2026 Financial Performance

    Reported worldwide sales of $247.2 million, a 5% increase year-over-year, driven by record pump shipments of over 29,000 units globally.

  • Achieved Positive Free Cash Flow

    Generated $4.8 million in non-GAAP free cash flow, a significant turnaround from a negative $21.2 million in Q1 2025, addressing a key concern from the prior year's financial baseline.

  • Substantial Improvement in Profitability

    Net loss significantly narrowed to $20.4 million from $130.6 million in Q1 2025, and adjusted EBITDA turned positive at $2.7 million, up from negative $79.9 million.

  • Reaffirmed Full-Year Guidance

    Maintained its 2026 financial guidance, including estimated sales of $1.065 billion to $1.085 billion and gross margin of 56% to 57%, signaling confidence in its outlook.


Analysis · TNDM · Industrial Applications And Services

The company demonstrated significant operational and financial improvements in Q1 2026, moving from negative to positive free cash flow and substantially reducing its net loss compared to the prior year. Record pump shipments and sales, coupled with improved gross margins, indicate strong product adoption and efficient operations. Reaffirming full-year guidance signals management's confidence in continued performance, building on the recent FDA clearance for its Control-IQ+ technology.

At the time of this filing, TNDM was trading at $20.04 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.98 to $29.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TNDM - Latest Insights

TNDM
May 21, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.76
Real-time Price: $19.45 info
Change: +$3.69 (+23%) info
Market Cap: $1.336B info
TNDM
May 15, 2026, 7:59 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.03
Real-time Price: $19.45 info
Change: +$5.42 (+39%) info
Market Cap: $1.336B info
TNDM
May 07, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.86
Real-time Price: $19.45 info
Change: -$1.41 (-7%) info
Market Cap: $1.336B info
TNDM
Apr 27, 2026, 9:21 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $20.75
Real-time Price: $19.45 info
Change: -$1.30 (-6%) info
Market Cap: $1.336B info
TNDM
Mar 27, 2026, 4:07 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $21.00
Real-time Price: $19.45 info
Change: -$1.55 (-7%) info
Market Cap: $1.336B info